# BrainStorm Cell Therapeutics Posts $0.68 Q3 Loss, Misses Estimate by $0.50

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/58797
Published: 2026-11-16T21:14:11.000Z
Updated: 2026-11-16T21:14:11.000Z
Section: Business

> Cash, cash equivalents and restricted cash totaled about $350,000 at Sept. 30, 2026, up from about $240,000 a year earlier.

BrainStorm Cell Therapeutics posted a third-quarter GAAP loss of $0.68 per share, missing the estimate by $0.50. Its cash, cash equivalents and restricted cash totaled about $350,000 at Sept. 30, 2026.

The combined cash total was about $240,000 at Sept. 30, 2025, making the 2026 balance about $110,000 higher than a year earlier.


